Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Clinical trial NCT06533579 · RECRUITING

Trial details

NCT number: NCT06533579
Sponsor: Vironexis Biotherapeutics Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

B-cell Acute Lymphoblastic Leukemia Large B-cell Lymphoma Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Marginal Zone Lymphoma Follicular Lymphoma Mantle Cell Lymphoma Diffuse Large B Cell Lymphoma High-grade B-cell Lymphoma Burkitt Lymphoma Primary Mediastinal Large B-cell Lymphoma (PMBCL)Non Hodgkin Lymphoma

Start date: 2025-05-30
Primary completion: 2027-06-01
Enrollment: 32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.